Abstracts tagged "Demographics"

Abstract Number: 0139 • ACR Convergence 2024
Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040
CLAUDIA MENDOZA-PINTO¹, IVET ETCHEGARAY MORALES², PAMELA MUNGUIA-REALPOZO¹, Socorro Méndez-Martínez³, Álvaro Montiel-Jarquín¹, Roberto Berra-Romani⁴, Fernanda Solis-Mendoza⁵ and Mario García-Carrasco⁶, ¹Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ⁴Benemérita Universidad Autónoma de PueblaPueblam, Puebla, Puebla, Mexico, ⁵Universidad de las Américas de Puebla, Puebla, Puebla, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder related to disability and premature mortality. Nowadays, the burden of RA is needed for healthcare…
Abstract Number: 1879 • ACR Convergence 2024
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Mario Bautista-Vargas¹, Adrian Romero-Ocampo², Juan José Pino Vélez³, juliana Muñoz-Bedoya⁴ and Diego Rosselli⁵, ¹Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ²Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, ³Universidad de Antioquia, Envigado, Antioquia, Colombia, ⁴Universidad Corpas, Bogotá, Colombia, ⁵Pontificia Universidad Javeriana, Bogotá, Colombia
Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
Abstract Number: 0143 • ACR Convergence 2024
Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021
GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
Abstract Number: 1941 • ACR Convergence 2024
No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders
Nicola Jackson¹, kim Nguyen², Tien Nguyen³, Meg James³ and Avis Ware⁴, ¹University of Cincinnati, Blue Ash, ²Trihealth Hospital, Cincinnati, ³University of Cincinnati, Cincinnati, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: Patient no-show and cancellation rates are long-standing problems in the healthcare system, affecting patient outcomes, revenue, system efficiency, and resource utilization. At the Hoxworth…
Abstract Number: 0144 • ACR Convergence 2024
More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups
John Chen¹, Tanya Selvam¹, Jeanne Darbinian², Christopher Macko¹, Nirmala Ramalingam², Joan Lo² and Lucy Liu², ¹Kaiser Permanente Oakland Medical Center, Oakland, CA, ²Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a disabling, autoimmune condition affecting up to as many as 17.6 million individuals worldwide. Epidemiologic evidence in the United States…
Abstract Number: 2334 • ACR Convergence 2024
Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
Murat Torgutalp¹, Valderilio Azevedo², Xenofon Baraliakos³, Filip Van den Bosch⁴, Jürgen Braun⁵, Alberto Cauli⁶, Laura Coates⁷, Vinod Chandran⁸, Torsten Diekhoff⁹, Floris van Gaalen¹⁰, Rodrigo Garcia Salinas¹¹, Lianne S Gensler¹², Niti Goel¹³, Alice Gottlieb¹⁴, Desiree van der Heijde¹⁵, Philip Helliwell¹⁶, Kay Geert Hermann¹⁷, Umut Kalyoncu¹⁸, Uta Kiltz¹⁹, Robert Lambert²⁰, Ying Ying Leung²¹, Maria Llop²², Alejandra Lopez²³, Miranda van Lunteren²⁴, Ajesh Maharaj²⁵, Walter Maksymowych²⁶, Helena Marzo-Ortega²⁷, Ashish J Mathew²⁸, Philip Mease²⁹, Peter Nash³⁰, Mikkel Ostergaard³¹, Fabian Proft³², Mikhail Protopopov³³, Sherry Rohekar³⁴, RUXANDRA ELENA SCHIOTIS³⁵, Joachim Sieper³⁶, Enrique R. Soriano³⁷, Lai-shan Tam³⁸, James Wei³⁹, Nelly Ziade⁴⁰, Dafna Gladman⁴¹ and Denis Poddubnyy⁴², and AXIS Cohort Investigators, ¹Charite Universitatsmedizin - Berlin, Berlin, Germany, ²Department of Internal Medicine, Universidade Federal of Paraná, Curitiba, Brazil, Curitiba, Brazil, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany., Herne, Germany, ⁶University of Cagliari, Cagliari, Italy, ⁷University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁸University of Toronto, Toronto, ON, Canada, ⁹Charite Universitatsmedizin Berlin, Berlin, Germany, ¹⁰LUMC, Leiden, Zuid-Holland, Netherlands, ¹¹Hospital Italiano La Plata, La Plata, Argentina, ¹²Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Caduceus Biomedical Consulting, Duke University, Durham, NC, ¹⁴Department of Dermatology, Icahn School of Medicine, New York, NY, USA., New York, NY, ¹⁵Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, ¹⁷Charite Medical School, Berlin, Germany, ¹⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ²⁰University of Alberta, Edmonton, AB, Canada, ²¹Singapore General Hospital, Singapore, Singapore, ²²Hospital Parc Tauli, Sabadell, Spain, ²³Centro Dermatológico del Country, Guadalajara, Jalisco, Mexico, Guadalajara, Mexico, ²⁴Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²⁵Department of Internal Medicine & Therapeutics, Faculty of Health Sciences. Walter Sisulu University, Eastern Cape, South Africa, Eastern Cape, South Africa, ²⁶Department of Medicine, University of Alberta, Edmonton, AB, Canada; CARE Arthritis, Edmonton, AB, Canada, Edmonton, Canada, ²⁷NIHR Leeds BRC, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, ²⁸Christian Medical College, Vellore, Tamil Nadu, India, ²⁹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³⁰School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ³¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³³Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³⁴Western University, London, Ontario, Canada, London, Canada, ³⁵SPITAL CLINIC DE BOLI INFECTIOASE CLUJ NAPOCA, Cluj-Napoca, Romania, ³⁶Charité University Medicine Berlin, Berlin, Germany, ³⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³⁸The Chinese University of Hong Kong, New Territories, Hong Kong, ³⁹Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China), ⁴⁰Saint-Joseph University, Beirut, Lebanon, ⁴¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴²Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Axial involvement, affecting the sacroiliac joints (SIJ) and/or spine, is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Previous…
Abstract Number: 0185 • ACR Convergence 2024
New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
Jonathan Katz¹, Ang Yu², Felix Elwert², Robert Greenlee³, David Gazeley⁴, Ann Rosenthal⁵, Jenna Cormier⁵, Bryn Sutherland⁵, Shalvi Parikh⁶, Yiran Jiang⁷ and Christie Bartels⁸, ¹University of Wisconsin Hospitals and Clinics, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³Marshfield Clinical Research Institute, Marshfield, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mississippi Delta Family Medicine Residency, Greenville, MS, ⁷Annapolis Rheumatology, Washington, DC, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations. SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…
Abstract Number: 2460 • ACR Convergence 2024
Severe Gastrointestinal Involvement in Systemic Sclerosis: A New “Transversal” Subset of Disease to Be Prioritised for Intervention Trials
Marco Minerba¹, Riccardo Bixio², Seda Colak³, Stefano Di Donato⁴, Lesley-Anne Bissell⁵ and Francesco Del Galdo⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²University of Verona, Verona, Verona, Italy, ³Gulhane Training and Research Hospital, Ankara, Turkey, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Gastrointestinal (GI) involvement is the most frequent internal complication of systemic sclerosis (SSc) and, when severe, it has a major influence on patient function.…
Abstract Number: 0211 • ACR Convergence 2024
Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
Riti Kotamarti¹ and Veena Patel², ¹Dell Seton Medical Center, Austin, TX, ²Dell Medical School - UT Health Austin, Austin, TX
Background/Purpose: Patients with SLE have high rates of hospitalizations annually and require careful coordination of care in both the inpatient and outpatient setting. Prior analyses…
Abstract Number: 2507 • ACR Convergence 2024
IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
Frederico Pinheiro¹, Cristina Orikaza², Gerson Keppeke³, Emília Sato² and Alexandre de Souza⁴, ¹Universidade Federal de Sao Paulo - UNIFESP, São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, ⁴UNIFESP-EPM, São Paulo, SP, Brazil
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It…
Abstract Number: 0232 • ACR Convergence 2024
Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study
Seyyid Bilal Acikgoz¹, Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel², Sylvia Sangwa⁴, Elliot Hepworth² and Sibel Aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Laura Coates¹, Carlo Selmi², Philip Mease³, Alexis Ogdie⁴, Francois Nantel⁵, Frederic Lavie⁶, Mohamed Sharaf⁷, Oyediran Adelakun⁸, Emmanouil Rampakakis⁹, Laura Pina Vegas¹⁰ and Lihi Eder¹¹, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Nantel MedSci Consult, Montreal, QC, Canada, ⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁷Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁸Janssen Research & Development, LLC, Titusville, NJ, ⁹McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…
Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Eric Morand¹, Cristina Arriens², Laura Geraldino³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁶, Ravi Koti⁵, Subhashis Banerjee⁵ and Ronald Van Vollenhoven⁷, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Salma Al Fazazi³, Vanesa Calvo-Rio⁴, Mónica Renuncio-García⁵, Adrián Martín-Gutiérrez⁶, Amparo Sánchez-López⁷, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁷, Maria Rodríguez-Vidriales¹ and Ricardo Blanco-Alonso⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ³Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Sai Shanmukha Sreeram Pannala¹, fares Saliba², Medha Rajamanuri³ and Veena Katikineni⁴, ¹Staten Island University Hospital, Northwell Health, staten island, new york city, NY, ²Staten Island University Hospital, Staten Island, NY, ³Southern Illinois University School of Medicine, Springfield, IL, ⁴Providence, Victorville, CA
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].